Phase 2 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older
- You have uterine cancer that has come back, spread to other parts of the body, or has not been treated with surgery, and this has been confirmed through a biopsy or standard medical scans (such as CT, PET/CT, MRI, bone scan, x-ray, or ultrasound)
- You have at least one area of cancer detected by medical scans that is located somewhere other than the liver
- You are willing to be told about the nature of the study, sign a consent form, and follow the study guidelines
- If you are currently taking or have recently stopped taking tamoxifen, you must wait 8 weeks before having the study scan; if you recently stopped taking fulvestrant, you must wait 28 weeks before having the study scan
Who may not be able to join:
- Women who are pregnant at the time of screening are not eligible; a urine pregnancy test will be done before the study injection for women who could potentially be pregnant
- People who are unable to tolerate or go through the imaging procedures required for the study, as determined by a doctor
- People who have any current medical condition, illness, or disorder that a doctor believes could put them at risk or prevent them from safely completing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Neil Taunk, MD, Abramson CC
Phone: 2155736569
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
rate of FES positivity in ER+ uterine cancer
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.